Videos
Opthea, a public company listed on the Australian Stock Exchange, is developing OPT-302, a novel therapy for wet age-related macular degeneration (AMD). The company’s lead…
Read MoreNew to the anterior segment arena, Z Lens was founded by Paul Beer, MD, and Edward Eveleth. Dr. Beer has more than 28 years’ experience…
Read MoreAvedro’s chief medical officer, Rajesh K. Rajpal, MD, said 2016 marked the first US Food and Drug Administration approval of a collagen cross-linking (CXL) device,…
Read MoreAppellis CEO Cedric Francois delivered an update on his company’s fully enrolled Phase III Filly trial of APL-2, a peptide targeting the C3 inhibitor in…
Read MorePaul Chaney, president and CEO, PanOptica, brought the OIS@AAO crowd up to speed on the progress of PAN-90806, a topical eyedrop for the treatment of…
Read MoreJason Slakter, CEO, Ohr Pharmaceutical, told OIS@AAO attendees that the company is enrolling patients in a Phase III clinical trial to test the efficacy of…
Read MoreSalutaris Medical Devices, Inc. (SalutarisMD®), is a clinical-stage company anticipating first sales revenue in early 2017. SalutarisMD is developing a minimally invasive treatment for Wet…
Read MoreCHICAGO—Inotek is committed to “transforming glaucoma treatments,” David Southwell, president and CEO, said here during the Ophthalmology Innovation Summit. Glaucoma is a $5.6 billion worldwide…
Read MoreCHICAGO—QLT, a biotechnology company, is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases, said David Saperstein, MD, chief…
Read MoreJeffrey Cleland, president and CEO, Graybug Vision, reports progress on its two treatments for wet age-related macular degeneration (wet AMD) and glaucoma. The company is…
Read MoreOcular Therapeutix entered into a collaboration with Regeneron Pharmaceuticals to develop a sustained-release formulation of Eylea (aflibercept), Ocular Therapeutix president, CEO, and chairman Amar Sawhney,…
Read MoreJoseph Gardner, president and CEO of Aerpio Therapeutics, acknowledged that his company is not alone in developing Tie2-activating agents to treat retinal disease, but at…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.